Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk <i>ERBB2</i> -Negative Breast Cancer

Claudine Isaacs, Rita Nanda, Christina Yau, A. Jo Chien, Dawn L. Hershman, Erica M. Stringer-Reasor, Anne M. Wallace, Alexandra Thomas, Christos Vaklavas, Amy S. Clark, Laura C. Kennedy, Amy Sanford, Judy C. Boughey, Kathy S. Albain, Lajos Pusztai, Kevin M. Kalinsky, Heather Beckwith, Nicole O. Williams, Hyo S. Han, Carla Falkson, Mili Arora, Anthony D. Elias, Paula R. Pohlmann, Mariya Rozenblit, Natalie Marshall, Yunn-Yi Chen, Meghna S. Trivedi, Julia E. McGuinness, Frederick M. Howard, Nan Chen, Katia Khoury, Rachael B. Lancaster, Kay T. Yeung, Emily Douglas, Mei Wei, Candace Mainor, Barbara LeStage, Amy L. Delson, Adam L. Asare, Lamorna Brown-Swigart, Gillian L. Hirst, Jeffrey B. Matthews, Jane Perlmutter, W. Fraser Symmans, Douglas Yee, Nola M. Hylton, Laura J. van ’t Veer, Hope S. Rugo, Angela M. DeMichele, Donald A. Berry, Laura J. Esserman

Open source

DOI: 10.1001/jamaoncol.2026.2576
Published: 2026-09-01
Container: JAMA Oncology
Publisher: American Medical Association (AMA)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1001/jamaoncol.2026.2576,
  title = {Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk
                    <i>ERBB2</i>
                    -Negative Breast Cancer},
  author = {Claudine Isaacs and Rita Nanda and Christina Yau and A. Jo Chien and Dawn L. Hershman and Erica M. Stringer-Reasor and Anne M. Wallace and Alexandra Thomas and Christos Vaklavas and Amy S. Clark and Laura C. Kennedy and Amy Sanford and Judy C. Boughey and Kathy S. Albain and Lajos Pusztai and Kevin M. Kalinsky and Heather Beckwith and Nicole O. Williams and Hyo S. Han and Carla Falkson and Mili Arora and Anthony D. Elias and Paula R. Pohlmann and Mariya Rozenblit and Natalie Marshall and Yunn-Yi Chen and Meghna S. Trivedi and Julia E. McGuinness and Frederick M. Howard and Nan Chen and Katia Khoury and Rachael B. Lancaster and Kay T. Yeung and Emily Douglas and Mei Wei and Candace Mainor and Barbara LeStage and Amy L. Delson and Adam L. Asare and Lamorna Brown-Swigart and Gillian L. Hirst and Jeffrey B. Matthews and Jane Perlmutter and W. Fraser Symmans and Douglas Yee and Nola M. Hylton and Laura J. van ’t Veer and Hope S. Rugo and Angela M. DeMichele and Donald A. Berry and Laura J. Esserman},
  year = {2026},
  journal = {JAMA Oncology},
  doi = {10.1001/jamaoncol.2026.2576},
  url = {https://doi.org/10.1001/jamaoncol.2026.2576}
}

RIS

TY  - JOUR
TI  - Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk
                    <i>ERBB2</i>
                    -Negative Breast Cancer
AU  - Claudine Isaacs
AU  - Rita Nanda
AU  - Christina Yau
AU  - A. Jo Chien
AU  - Dawn L. Hershman
AU  - Erica M. Stringer-Reasor
AU  - Anne M. Wallace
AU  - Alexandra Thomas
AU  - Christos Vaklavas
AU  - Amy S. Clark
AU  - Laura C. Kennedy
AU  - Amy Sanford
AU  - Judy C. Boughey
AU  - Kathy S. Albain
AU  - Lajos Pusztai
AU  - Kevin M. Kalinsky
AU  - Heather Beckwith
AU  - Nicole O. Williams
AU  - Hyo S. Han
AU  - Carla Falkson
AU  - Mili Arora
AU  - Anthony D. Elias
AU  - Paula R. Pohlmann
AU  - Mariya Rozenblit
AU  - Natalie Marshall
AU  - Yunn-Yi Chen
AU  - Meghna S. Trivedi
AU  - Julia E. McGuinness
AU  - Frederick M. Howard
AU  - Nan Chen
AU  - Katia Khoury
AU  - Rachael B. Lancaster
AU  - Kay T. Yeung
AU  - Emily Douglas
AU  - Mei Wei
AU  - Candace Mainor
AU  - Barbara LeStage
AU  - Amy L. Delson
AU  - Adam L. Asare
AU  - Lamorna Brown-Swigart
AU  - Gillian L. Hirst
AU  - Jeffrey B. Matthews
AU  - Jane Perlmutter
AU  - W. Fraser Symmans
AU  - Douglas Yee
AU  - Nola M. Hylton
AU  - Laura J. van ’t Veer
AU  - Hope S. Rugo
AU  - Angela M. DeMichele
AU  - Donald A. Berry
AU  - Laura J. Esserman
PY  - 2026
JO  - JAMA Oncology
DO  - 10.1001/jamaoncol.2026.2576
UR  - https://doi.org/10.1001/jamaoncol.2026.2576
ER  -

APA

Isaacs, C., Nanda, R., Yau, C., Chien, A. J., Hershman, D. L., Stringer-Reasor, E. M., Wallace, A. M., Thomas, A., Vaklavas, C., Clark, A. S., Kennedy, L. C., Sanford, A., Boughey, J. C., Albain, K. S., Pusztai, L., Kalinsky, K. M., Beckwith, H., Williams, N. O., Han, H. S., Falkson, C., Arora, M., Elias, A. D., Pohlmann, P. R., Rozenblit, M., Marshall, N., Chen, Y., Trivedi, M. S., McGuinness, J. E., Howard, F. M., Chen, N., Khoury, K., Lancaster, R. B., Yeung, K. T., Douglas, E., Wei, M., Mainor, C., LeStage, B., Delson, A. L., Asare, A. L., Brown-Swigart, L., Hirst, G. L., Matthews, J. B., Perlmutter, J., Symmans, W. F., Yee, D., Hylton, N. M., Veer, L. J. V. ’., Rugo, H. S., DeMichele, A. M., Berry, D. A., & Esserman, L. J. (2026). Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk <i>ERBB2</i> -Negative Breast Cancer. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2026.2576

Source records

crossref · retrieved 2026-09-25T08:19:16.758Z